February 26, 2017 1:54 AM ET

Pharmaceuticals

Company Overview of Bluefish Pharmaceuticals AB

Company Overview

Bluefish Pharmaceuticals AB, together with its subsidiaries, develops, manufactures, and markets generic pharmaceuticals in Sweden and internationally. It provides a portfolio of generic pharmaceuticals in various therapeutic areas, such as cardiovascular, central nervous system, gastrointestinal, diabetes, oncology, dermatology, respiratory, inflammatory, genito-urinary, antifungal, antiviral, endocrinology, analgesic, and antibiotics. The company sells its products through a network of independent wholesalers and pharmacies. Bluefish Pharmaceuticals AB was founded in 2005 and is headquartered in Stockholm, Sweden.

Gävlegatan 22

Stockholm,  113 30

Sweden

Founded in 2005

100 Employees

Phone:

46 8 51 91 16 00

Fax:

46 8 51 91 16 90

Key Executives for Bluefish Pharmaceuticals AB

Founder, Chief Executive Officer, President and Director
Age: 42
Chief Financial Officer
Age: 45
Chief Operating Officer
Age: 51
Head of development and Quality Assurance
Chief Business Development Officer
Age: 40
Compensation as of Fiscal Year 2016.

Bluefish Pharmaceuticals AB Key Developments

Bluefish Pharmaceuticals AB Reports Consolidated and Parent Earnings Results for the Fourth Quarter and Year Ended December 31, 2016; Provides Earnings Guidance for the Year 2017

Bluefish Pharmaceuticals AB reported consolidated and parent earnings results for the fourth quarter and year ended December 31, 2016. For the second half, on consolidated basis, the company reported net sales of SEK 162,126000 compared to SEK 146,567,000 a year ago. Operating profit was SEK 8,574,000 compared to loss of SEK 5,284,000 a year ago. Profit after financial items was SEK 5,394,000 compared to loss of SEK 8,147,000 a year ago. Profit for the period was SEK 4,204,000 or SEK 0.05 per share before and after dilution compared loss of SEK 9,584,000 or SEK 0.12 per share before and after dilution a year ago. EBITDA was SEK 21,943,000 compared to SEK 10,052,000 a year ago. Cash used in operating activities was SEK 10,494,000 compared to cash flow from operating activities of SEK 45,403,000 a year ago. For the year, on consolidated basis, the company reported net sales of SEK 311,627,000 compared to SEK 283,229,000 a year ago. Operating profit was SEK 3,857,000 compared to loss of SEK 15,277,000 a year ago. Loss after financial items was SEK 1,301,000 compared to SEK 19,857,000 a year ago. Loss for the period was SEK 3,628,000 or SEK 0.04 per share before and after dilution compared to SEK 22,175,000 or SEK 0.27 per share before and after dilution last year. Cash used in operating activities was SEK 33,087,000 compared to cash flow from operating activities of SEK 48,514,000 a year ago. EBITDA was SEK 29.1 million compared to SEK 12.8 million a year ago. For the second half, on parent basis, the company reported net sales of SEK 145,454,000 compared to SEK 142,351,000 a year ago. Operating profit was SEK 8,480,000 compared to loss of SEK 3,475,000 a year ago. Profit for the period was SEK 4,833,000 compared to loss of SEK 13,877,000 a year ago. For the year, on parent basis, the company reported net sales of SEK 283,438,000 compared to SEK 274,382,000 a year ago. Operating profit was SEK 2,371,000 compared to loss of SEK 12,195,000 a year ago. Loss for the period was SEK 4,464,000 compared to SEK 25,845,000 last year. The company expects higher sales growth and improved profitability for the year 2017.

Bluefish Pharmaceuticals Announces Earnings Results for the Second Quarter and Year to Date Ended June 30, 2016

Bluefish Pharmaceuticals announced earnings results for the second quarter and year to date ended June 30, 2016. For the quarter, net sales amounted to SEK 70.2 million against SEK 65.9 million a year ago. EBITDA was SEK 2.0 million against LBITDA of SEK 0.9 million a year ago. Basic loss per share was SEK 0.07 against SEK 0.10 a year ago. For the year-to-date, net sales amounted to SEK 149.5 million against SEK 136.7 million a year ago. EBITDA was SEK 7.2 million against SEK 2.7 million a year ago. Basic loss per share was SEK 0.10 against SEK 0.16 a year ago.

Bluefish Pharmaceuticals AB Reports Unaudited Consolidated and Parent Earnings Results for the First Quarter Ended March 31, 2016; Provides Earnings Guidance for the Year 2016; Reports Impairment for the First Quarter of 2016

Bluefish Pharmaceuticals AB reported unaudited consolidated and parent earnings results for the first quarter ended March 31, 2016. For the quarter, on consolidated basis, the company reported net sales of SEK 79.3 million against SEK 70.8 million a year ago. EBITDA was SEK 5.2 million against SEK 3.7 million a year ago. Operating loss was SEK 0.569 million against SEK 3.495 million a year ago. Net loss was SEK 1.8 million or SEK 0.02 per basic and diluted share against SEK 4.6 million or SEK 0.06 per basic and diluted share a year ago. The currency effect on earnings was negative at SEK 1.0 against SEK 1.0 a year ago, of which negative of SEK 0.6 against SEK 1.5 million a year ago is unrealized. Negative cash flow from operating activities was SEK 2.0 million against cash flow from operating activities of SEK 8.8 million a year ago. Currency fluctuations had a negative impact on EBITDA. The increase in sales is primarily attributable to countries outside the Nordic region. The increase in sales is also associated with an improvement in gross margin. For the first quarter of 2016, on parent basis, the company’s net sales were SEK 73.0 million against SEK 68.8 million a year ago. Operating loss was SEK 1.8 million against SEK 2.6 million a year ago. Loss for the period was SEK 3.153 million against SEK 3.851 million a year ago. For the first quarter of 2016, the company reported impairment losses on intangible assets of SEK 1.7 million against SEK 3.0 million a year ago. The growth in sales and improved profitability in 2015 has created a strong platform for the company's continued development. The company expects both sales and profitability to stabilize in 2016 at comparable levels to 2015, even though fluctuations will likely occur between quarters.

Similar Private Companies By Industry

Company Name Region
Abunon AB Europe
AcuCort AB Europe
Aditech Pharma AB Europe
Antarctic Pharma Europe
Apotek Produktion & Laboratorier AB Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Bluefish Pharmaceuticals AB, please visit www.bluefishpharma.se. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.